Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy
Brachytherapy, v 11(1), pp 47-52
2012
PMID: 22265437
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer.
Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy.
The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80–90
Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed.
These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.
Metrics
Details
- Title
- American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy
- Creators
- Akila N. Viswanathan - Harvard UniversitySushil Beriwal - University of Pittsburgh School of MedicineJennifer F. De Los Santos - University of AlabamaD. Jeffrey Demanes - Department of Radiation Oncology, David Geffen School of Medicine UCLA, Los Angeles, CADavid Gaffney - University of UtahJorgen Hansen - Dana-Farber Cancer InstituteEllen Jones - Department of Radiation Oncology, University of North Carolina, Chapel Hill, NCChristian Kirisits - Medical University of ViennaBruce Thomadsen - University of Wisconsin–MadisonBeth Erickson - Medical College of WisconsinAmerican Brachytherapy Society
- Publication Details
- Brachytherapy, v 11(1), pp 47-52
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000299851300007
- Scopus ID
- 2-s2.0-84856022087
- Other Identifier
- 991021897369104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging